These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30288088)

  • 21. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
    Inotai A; Mészáros A
    Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
    White WB; Faich G; Whelton A; Maurath C; Ridge NJ; Verburg KM; Geis GS; Lefkowith JB
    Am J Cardiol; 2002 Feb; 89(4):425-30. PubMed ID: 11835924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
    Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
    Moore RA; Derry S; Makinson GT; McQuay HJ
    Arthritis Res Ther; 2005; 7(3):R644-65. PubMed ID: 15899051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs.
    Grosser T; Ricciotti E; FitzGerald GA
    Trends Pharmacol Sci; 2017 Aug; 38(8):733-748. PubMed ID: 28651847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus
.
    Mazhar F; Haider N; Sultana J; Akram S; Ahmed Y
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):64-71. PubMed ID: 29208206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.